Skip to main content
NAUT logo

NAUT · Nautilus Biotechnology, Inc. · Webcasts, Transcripts & Audio

Track NAUT — free
$2.30 -0.02 (-0.86%) Play latest call Q3 2026 earnings call transcript
Market Cap
$295.50M
Shares
127.37M
Volume · Nov 16 1.74M Avg daily vol (3M) 5.87M

Nautilus Biotechnology, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Nautilus Biotechnology, Inc. (NAUT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-10-27
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
Confident tone Collaborations and grant funding Commercial launch timeline Proteoform platform differentiation
Revenue
$234,000
Diluted EPS
$-0.12
Gross margin
89.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-07-28
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Positive tone Broad scale program delays Strategic pivot to Proteoform Oncology expansion and sample types
Revenue
$190,000
Diluted EPS
$-0.11
Gross margin
92.1%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-28
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Confident tone Commercialization and customer engagement Voyager platform and broad-scale assay development Oncology proteoform target
Diluted EPS
$-0.12
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Confident tone Voyager instrument unveiling and early access program Proteomics platform and proteoform diversity Tau proteoform assay and collaborations
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Confident tone Tau proteoform assay and collaborations Broad-scale assay configuration / technology development Operational discipline and spending / runway
Revenue
$0
Diluted EPS
$-0.11
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Call Transcript
Confident tone Customer engagement and collaborations Tau proteoform manuscript and scientific validation Platform reproducibility and performance
Revenue
$0
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript
Confident tone Tau Proteoform Assay V&V Broad Scale Proteome / Platform Development Customer and Partnership Interest
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript
Positive tone Broadscale discovery Tau proteoform assay Probe optimization
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Cautious tone Proteoform data and modality progress Broad scale protein quantification milestone Proteomics market opportunity
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript
Positive tone Proteoform Technology Platform Development Metrics Product Launch Timeline
Diluted EPS
$-0.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Confident tone U.S. HUPO conference reception Supply chain and manufacturing readiness Key opinion leader and researcher engagement
Diluted EPS
$-0.15
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Positive tone Platform Launch Timeline R&D Progress and Reproducibility Single-Molecule Protein Decoding
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Nautilus Biotechnology, Inc. (NAUT) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.11
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Nautilus Biotechnology, Inc. (NAUT) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Nautilus Biotechnology, Inc. (NAUT) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Nautilus Biotechnology, Inc. (NAUT) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Nautilus Biotechnology, Inc. (NAUT) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Nautilus Biotechnology, Inc. (NAUT) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.19
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 webcasts
Key facts CIK 1808805 CUSIP 63909J108 13F (30d) 65 filings 54 filers Visit website Investor relations